# INSILICO AND EX-VIVO IMMUNOGENICITY ANALYSIS OF NCATS GENE THERAPY TEST

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2024 · $564,711

## Abstract

The Therapeutic Development Branch (TDB) in the Division of Preclinical Innovation (DPI) of NCATS advances novel therapeutics and technologies through preclinical and clinical stages of development. TDB initiated NCATS’ collaborative Rare Disease Platform Vector Gene Therapy (PaVe-GT) program. The program involves preclinical development and clinical evaluation of gene therapy products for rare diseases. In-silico and Ex-vivo analysis of the candidates is essential in de-risking the potential failure of the candidate in human subjects.

## Key facts

- **NIH application ID:** 11196158
- **Project number:** 75N91019D00024-P00002-759102300009-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** max moore
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $564,711
- **Award type:** —
- **Project period:** 2023-07-03 → 2026-07-02

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11196158

## Citation

> US National Institutes of Health, RePORTER application 11196158, INSILICO AND EX-VIVO IMMUNOGENICITY ANALYSIS OF NCATS GENE THERAPY TEST (75N91019D00024-P00002-759102300009-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11196158. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*